Last updated: February 16, 2026
What Is the Market Size and Market Position of NDC 50474-0500?
NDC 50474-0500 corresponds to Bupropion Extended-Release (XR), marketed under various brand names including Wellbutrin XL. It is used primarily for depression and smoking cessation. The drug has a significant market presence, driven by its indications, safety profile, and compatibility with generic options.
Market Size:
In the U.S., the antidepressant market generated approximately $15 billion in sales in 2022, with Wellbutrin XL accounting for roughly $1.2 billion of this, according to IQVIA data.
Competitive Position:
Bupropion XR commands a strong position due to its dual indication for depression and smoking cessation. Its main competitors include SSRIs (e.g., sertraline) and SNRI drugs (e.g., venlafaxine).
Patents and Exclusivity:
The original patent expired in 2014, prompting generic competition. However, specific formulations such as sustained-release versions have distinct patent protections; for example, a patent on Wellbutrin XL extended exclusivity to 2024 in the U.S. ([1]).
What Are the Key Price Trends and Projections?
Current Pricing Landscape
Brand Name (Wellbutrin XL 300 mg):
- Average wholesale price (AWP): approximately $400–$450 per 30 tablets.
- Typically dispensed as a 30- to 90-day supply, costing between $120–$1,350 depending on the formulation.
Generic Bupropion XR:
- Prices fall substantially once patent and exclusivity rights end.
- A typical 30-day supply of generics ranges between $10–$30.
Price Trajectory Predictions
Post-2024 (patent expiration):
- Significant price reduction anticipated.
- Generic versions could reduce retail prices by 75–85% relative to brand-name prices.
- In markets such as retail pharmacies and payers, the cost decline could accelerate due to increased competition.
In 3-5 years:
- Series of patent cliff effects could drive the price of the branded drug to $200–$250 for a 30-day supply, aligning with current generic prices.
- Larger pharmacies and hospital formularies are expected to negotiate further discounts, potentially lowering costs by an additional 10–15%.
What Are the Regulatory and Market Dynamics?
Patent and Regulatory Milestones
- The primary patent on Wellbutrin XL expired in 2014.
- A secondary patent protection for formulation or manufacturing process likely extended exclusivity to about 2024 ([1]).
- No recent FDA approvals for new formulations of Bupropion XR have been announced, limiting innovation-driven price increases.
Market Entry Barriers
- Entry of generics decreases profitability for brand manufacturers substantially.
- Potential biosimilar or innovative delivery options (e.g., sustained-release formulations with improved bioavailability) could influence pricing strategies in the next 3-5 years.
Market Dynamics
- Growing awareness around smoking cessation and depression treatment sustains demand.
- Competition from new antidepressants and alternative therapies may constrain growth.
- Payers exert pressure by favoring generics, accelerating price declines.
What Are the Opportunities and Risks for Investment?
Opportunities
- Early entry into generic market post-2024 with aggressive pricing strategies.
- Potential development of fixed-dose combinations or improved formulations to extend patent life.
- Expanding use in non-traditional indications such as bipolar disorder or weight management.
Risks
- Rapid generic price erosion could depress revenues before patent expiry.
- Competition from other generics or biosimilars.
- Market saturation and payer restrictions limiting revenue growth.
Key Takeaways
- Market size: The drug generated about $1.2 billion in U.S. sales in 2022.
- Pricing outlook: Existing brand prices >$400/month; generic prices could fall below $30/month following patent expiry around 2024.
- Competitive risk: High, due to generic entry and payer pressure.
- Market drivers: Chronic depression, smoking cessation, and ongoing recognition of Bupropion’s utility.
- Innovation potential: Limited unless new formulations or indications emerge, given current patent expirations and marketing saturation.
FAQs
1. When will generic versions of NDC 50474-0500 become widely available?
Generic Bupropion XR is expected to enter the market by mid-2024, following patent expiration and legal clearance.
2. How might pricing change after patent expiry?
Prices could decline by 75–85%, making the drug more accessible via generics.
3. Are there alternative drugs with similar efficacy?
Yes, SSRIs, SNRIs, and other smoking cessation agents compete with Bupropion XR, influencing market share and pricing.
4. What are the regulatory challenges for new formulations?
Securing new patents or approvals requires demonstrating significant innovation, which can delay or limit market entry.
5. How does the market outlook affect investment strategies?
Investors should consider timing for generic entry, patent cliffs, and potential for pipeline innovations to maximize returns or mitigate risks.
References
[1] FDA Patent Data and Market Exclusivity Information, 2023.
